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1. Introduction 
As part of a program to examine the pharmaco- 
kinetics of the angiotensin converting enzyme inhib- 
itor BPPga (also known as SQ 20,88 1): 
1 2 3 4 5 6 7 8 9 
<Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro 
we have synthesized a series of its analogs containing 
L-3,4dehydroproline [l] (A3Pro) in place of the 
prolme residues at position 3,5,8 or 9. These analogs 
were synthesized to facilitiate preparation of tritium- 
labelled BPPg, by catalytic hydrogenation i tritium 
gas of the unsaturated carbon-carbon bond of AaPro. 
However, during the course of our studies, the A3Pro- 
BPP,, analogs were assayed in vitro and in vivo for 
their abilities to inhibit angiotensin converting 
enzyme (ACE). All of the analogs were found to be 
more potent than BPP,, itself. 
Several bradykinin potentiating peptides (BPP) 
have been isolated from the venom of Bothrops 
jararaca, a South American pit viper [2,3]. The 
most potent is the nonapeptide, BPPg,. Part, if not 
all, of the effects of BPPg, as a bradykinin poten- 
tiating agent are attributable to its ability to inhibit 
angiotensin converting enzyme [4,5]. Gavras and 
colleagues [6,7] have shown that BPPg,, injected 
intravenously at l-4 mg/kg body wt, acts as a 
potent anti-hypertensive agent in patients with renin- 
related hypertension. Of equal or greater importance 
is that some patients with essential hypertension can 
also be made normotensive by treatment with BPPg, 
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in combination with a diuretic such as furosemide 
[VI. 
The means by which BPP9, exerts its anti-hyper- 
tensive ffects are not fully understood, but one of 
its major mechanisms of action is that of inhibition 
of angiotensin converting enzyme. In addition to its 
ability to inhibit the conversion of angiotensin I (AI) 
into the potent vasoconstrictor ctapeptide angio- 
tensin II (AII) [ 10,111, BPPg, can also prevent he 
inactivation of the hypotensive hormone bradykinin 
by ACE [5]. It is still uncertain whether the blood 
pressure lowering effect of BPPg, is attributable to 
inhibition of the formation of AII, to the preserva- 
tion of bradykinin, or to actions as yet undefined. 
In efforts to understand further the mechanisms of 
action of BPP,, and to determine its metabolic fate in 
vivo, we have synthesized 5 analogs of BPPg, con- 
taining L-3,4dehydroproline (A%o) in place of the 
proline residues at position 3,5,8, or 9 of BPPg,: 
[L-AaPro3]-BPPg,; [L-PaPros]-BPP9a; 
[ L-A’Pro’]-BPPg,; [ L-AsPro’]-BPPg,; 
[LAaPro3*g]-BPPg, 
Upon catalytic reduction in tritium gas, the double 
bond of the AaPro residue can be reduced to yield 
BPPg, labelled with two tritium atoms per original 
dehydroproline residue [121. 
2. Materials and methods 
The A3Pro-BPPg, analogs were synthesized by the 
solid-phase t chnique using a Schwarz-Mann automatic 
peptide synthesizer, as described for AaPro-bradykinin 
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analogs [ 131. The a-amino nitrogen or arginine was 
protected with the amyloxycarbonyl (Aoc) group 
and the guanidino nitrogen with the tosyl protecting 
group. P-Mercaptoethanol (1%) was added to the 
deprotection reagent after incorporation of trypto- 
phan in order to prevent oxidation of its indole ring 
[ 141. To avoid diketopiperazine formation from the 
Pro-Pro dipeptide resin, inverse addition of dicyclo- 
hexylcarbodiimide (DCC) and Boc-Be for the third 
coupling was carried out according to the recom- 
mendation in [ 151. Cleavage of a given peptide from 
the resin, with simultaneous removal of protecting 
groups and formation of the carboxyl terminal acid, 
was effected with anhydrous, liquid hydrogen fluo- 
ride (HF) in the presence of 10% anisole. The crude 
deprotected peptides were purified by gel filtration 
and partition chromatography on Bio-Gel P-2, 
Sephadex G-25, and Sephadex LH-20, and were 
analyzed for purity as in [ 13 1. 
Table 1 
Inhibition of angiotensin converting enzyme by 
A%‘ro-BPPg, analogs 
Peptide 
BPP98 
[L-A Pro”]-BPPg, 
[L-A3Pro5]-BPPga 
[L-A%o*]-BPPga 
[ L-AJPro9]-BPPga 
[ L-A3Pro3+BPPga 
Assay protocol is as in section 2 and also in [ 161 
homogeneous, as judged by thin-layer chromatography, 
paper electrophoresis, and high-performance liquid 
chromatography. By these techniques, the analogs 
were essentially indistinguishable from BPPg,. Each 
analog on amino acid analysis showed the requisite 
residues in the theoretical molar ratios. 
The analogs were tested in vitro for their abilities 
to inhibit the activity of angiotensin converting 
enzyme. Inhibitory activity was measured in terms 
of the ability of a given analog to inhibit hydrolysis 
of the substrate [3H]benzoyl-Gly-His-Leu 
([aH]Hip-His-Leu) by ACE partially purified 
from human urine. Enzyme was used in a quantity 
sufficient to hydrolyze 8% of substrate ( [3H]Hip- 
His-Leu plus unlabelled Hip-His-Leu at 100 PM) 
on incubation at 37°C for 15 min in Hepes buffer 
containing 0.1 M NaCl and 0.75 M Na$O_, at pH 8 
[ 161. Inhibitor concentrations varied from 10bQ-- 
lo-” M. 
Each of the A3Pro-BPP9, analogs was assayed in 
vivo for the ability to inhibit the vasopressor esponse 
to angiotensin I. Normotensive Sprague-Dawley rats 
were anesthetized with pentobarbital, 50 mg/kg intra- 
peritoneally. Cannulas were inserted for intravenous 
injection and for direct measurement of mean arterial 
blood pressure. Angiotensin I, 200 ng/kg, was injected 
intravenously at timed intervals before and after 
injection of an inhibitor. Systemic arterial blood 
pressure was recorded via the femoral artery with a 
Statham pressure transducer connected to a poly- 
graph recorder. 
In vitro, the AsPro-BPPga analogs inhibit the 
activity of angiotensin converting enzyme. That con- 
centration of inhibitor which reduces enzyme activity 
by half is defined as the inhibitory potency and is 
expressed as the Zsc, value. The Iso values for BPP9, 
and its A3Pro analogs are listed in table 1. Two of 
the analogs, [L-A3Pro3]-BPPga and [L-A3ProS]- 
BPPga, proved to be -40-times more potent than 
BPPga itself (respective I,,-, values, 0.6 nM, 0.6 nM, 
and 25 nM). [L-A3Pro8]-BPPga (Zse, 0.3 nM) and 
[L-A3Pro9]-BPP9, (Zsc,0.2 nM) are -loo-times 
more potent than BPP,, . The doubly substituted 
analog [L-A3ProJP]-BPPga (Z5e, 0.5 nM) is -5O-times 
more potent than BPPg,. 
Each of the A3Pro-BPPga analogs is also active in 
vivo in inhibiting the vasopressor esponse to angio- 
tensin I in anesthetized normotensive rats (iig.1). 
[ L-A3Proq]-BPPga is not only as potent as Squibb’s 
new ACE inhibitor, Captopril (SQ 14,225) [17,18], 
on a molar basis but also has a longer duration of 
action. The doubly substituted analog [L-A3Pro3s9]- 
BPPg, is also as active as the A3Pro3 analog but has 
a slightly shorter duration of action. As expected, 
the durations of action of the analogs were increased 
with increasing dosage (fig.lb). 
3. Results 4. Discussion 
Each of the synthetic A3Pro-BPPg, analogs was BPPga and related peptides exert their effects on 
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Fig. 1. Effects of intravenous APro-BPP9, analogs on the 
vawpressor esponse to angiotensin I(200 r&kg) in normo- 
tensive rats. (a) Inhibitor at 0.45 pmol/kg; (b) Inhibitor at 
1.37 rmol/kg. Blood pressure effects of angiotensin I given 
after inhibitor are expressed in terms of % of the control 
response. 
ACE by binding at or near the active site of the 
enzyme. The high potencies of the A3Pro-BPPga 
analogs may be due to preferential n--71 interaction 
of the deformed electron cloud of the double bond 
of the dehydroproline residue with binding sites on 
the enzyme. The high potency of [L-AsPro’]--BPPg, 
emphasizes the importance of the C-terminal proline 
residue for binding to the active site of the enzyme 
[ 19,201. It has been postulated that introduction of 
unsaturation into a binding element of a peptide can 
enhance its affinity for some of its receptors [21]. 
For example, [L-A%o’]-oxytocin has increased 
uterotonic effects compared to oxytocin itself [21]. 
By analogy, it would appear that inhibitor-enzyme 
binding is similarly influenced. 
In addition, the double bond of dehydroproline, 
allylic to the asymmetric center, tends to restrict the 
conformational flexibility of the proline ring. There- 
fore, it is reasonable to consider that substitution of 
dehydroproline into the BPP,, sequence may restrict 
further the number of possible conformations which 
the peptide can assume and thereby alter its inhibitory 
potency [13,22]. 
In experiments using our assay technique, results 
obtained with Squibb’s new synthetic ACE inhibitor, 
Captopril (SQ 14,225) [17,18], are highly variable 
(Is,,, l-20 nM), possibly owing to the lability of the 
drug. To our knowledge, [LA3Prog]-BPPg, is the 
most potent ACE inhibitor known. Since the costs 
of synthesis of BPPg, and its A3Pro analogs are 
essentially the same, there may be distinct economic 
and manufacturing advantages in the use of 
[Ld3Pro9]-BPPg, for the treatment of renovascular 
and essential hypertension. 
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